We have capabilities, experience and expertise in chem-informatics, synthetic methodology, computational chemistry, laboratory automation, library synthesis, medicinal chemistry, natural products chemistry, organic synthesis on milligram to multi-gram scale, pharmaceutical properties (ADME/Tox) analysis and optimization, structure-based drug design, and drug discovery and development. We have in place protocols for hit/scaffold assessment, triage, and optimization; lead optimization for potency, selectivity and pharmaceutical properties; and identification and development of clinical candidates.
We have a strong tradition of collaborative research with internal as well as external scientists that has resulted in significant scientific contributions in the areas of chemical biology and drug discovery and development and to the advancement of nearly forty small molecules into clinical trials, as well as the discovery and development of two marketed cancer drugs.
Two Cores comprise the UPCDC:
The Medicinal Chemistry Core is led by the PI, Professor Donna Huryn, and contributes to hit validation and triage; hit-to-lead activities; the design and synthesis for Structure Activity Relationships (SAR) and Structure Property Relationships (SPR) development (e.g., lead optimization); design and synthesis of analogs to address ADME/Tox deficiencies; and the preparation of labeled versions of lead compounds.
The Synthetic Chemistry Core has responsibility for synthesis route selection and methodology development; library synthesis; natural product chemistry; analytical chemistry support; compound storage, handling and shipping; and scale-up synthesis. Professor Peter Wipf leads the Synthetic Chemistry Core